FINCH THERAPEUTCS GRP INC - FNCH STOCK NEWS

Finch Therapeutics (Nasdaq: FNCH) announced it will regain full rights to develop and commercialize FIN-524 and FIN-525 from Takeda, effective November 17, 2022. This decision follows Takeda's review and termination of their collaboration. Finch has received over $44 million from Takeda during the collaboration, which includes a $10 million upfront payment. Finch will also gain access to valuable data and intellectual property generated during the partnership, including a library of bacterial strains. The company aims to explore future collaboration opportunities to advance these investigational therapies for inflammatory bowel disease.

Finch Therapeutics (Nasdaq: FNCH) reported second-quarter financial results revealing a net loss of $22.7 million, up from $15.2 million a year earlier, primarily due to increased operating expenses and decreased revenue from collaboration. The company is on track to enroll patients in the PRISM4 Phase 3 trial of CP101 for recurrent C. difficile infection later this year, with promising data from the PRISM-EXT Phase 2 trial. Finch anticipates submitting an IND for FIN-211, targeting children with autism and gastrointestinal symptoms, in Q4 2022. Cash reserves are projected to sustain operations until Q1 2024.

Finch Therapeutics Group, a clinical-stage microbiome therapeutics company, announced CEO Mark Smith's participation in investor conferences. The conferences are the Jefferies Healthcare Conference on June 10, 2022, at 8:00 am ET, and the JMP Securities Life Sciences Conference on June 15, 2022, at 2:00 pm ET, both in New York. Finch's lead candidate, CP101, is in late-stage development for preventing recurrent C. difficile infections and has received FDA designations. The event will be webcast live on Finch's website and archived for 30 days.

Finch Therapeutics Group, a clinical-stage microbiome therapeutics company (Nasdaq: FNCH), announced that CEO Mark Smith, PhD, will present an overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting May 24, 2022, at 7:00 am ET. Finch focuses on developing novel orally administered biological drugs, with its lead candidate, CP101, in late-stage clinical trials for preventing recurrent C. difficile infections. The company also explores treatments for children with autism and partners with Takeda for inflammatory bowel disease therapies.

Finch Therapeutics Group (Nasdaq: FNCH) announced significant updates including the FDA lifting the clinical hold on its investigational new drug (IND) application for CP101. Enrollment for the PRISM4 Phase 3 trial is expected to resume in H2 2022. The company has drawn $15 million from a new $55 million debt facility, ensuring operational funding into Q2 2024. Despite a net loss of $24.6 million in Q1 2022, increased operating expenses were largely due to research and development efforts, while collaboration revenue fell to $354K from $3.6 million year-on-year.

Finch Therapeutics Group (Nasdaq: FNCH) announced a conference call and live webcast on May 16, 2022, at 8:00 am ET to discuss updates on its development programs. The call can be accessed at (833) 649-1186 for domestic callers and (270) 823-1080 for international callers, using conference ID 8451806. Finch specializes in microbiome therapeutics, with lead candidate CP101 in late-stage development for C. difficile infection prevention. Finch has also received Breakthrough Therapy and Fast Track designations from the FDA.

Finch Therapeutics Group (Nasdaq: FNCH) announced the lifting of the FDA's clinical hold on its IND application for CP101, an oral microbiome therapeutic targeting recurrent C. difficile infection. The FDA's decision follows Finch’s submission of information related to its SARS-CoV-2 screening procedures. Finch plans to resume enrollment in the Phase 3 PRISM4 study after completing necessary manufacturing and quality system updates. The company is also preparing for its AUSPIRE Phase 1b trial in children with autism spectrum disorder, aiming to provide updates alongside its Q1 2022 results.

Finch Therapeutics Group, Inc. (Nasdaq: FNCH) plans to reduce its workforce by 20% to concentrate on its key development programs for recurrent C. difficile infection and autism spectrum disorder. This strategic move aims to strengthen its financial position. The company is facing a clinical hold on its lead candidate CP101 due to issues related to FDA protocols for SARS-CoV-2 donor screening. Finch is awaiting feedback from the FDA after submitting a complete response to lift the hold. Financial guidance on the cash runway extension will be provided with upcoming Q1 results.

Finch Therapeutics (FNCH) reported Q4 and full year 2021 financial results, highlighting significant milestones including advancements in its CP101 for recurrent C. difficile infection and its ulcerative colitis program with Takeda. The company has paused CP101 development for chronic hepatitis B to focus resources on prioritized programs. Notable financials include a Q4 net loss of $19.1 million and a full-year net loss of $58.2 million, with R&D expenses rising to $14.8 million in Q4. Finch holds $133.5 million in cash, expected to last into mid-2023.